Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,276Revenue (TTM) $M784Net Margin (%)13.3Altman Z-Score5.0
Enterprise Value $M2,202EPS (TTM) $1.5Operating Margin %16.6Piotroski F-Score4
P/E(ttm)22.1Beneish M-Score-2.5Pre-tax Margin (%)16.0Higher ROA y-yN
Price/Book2.610-y EBITDA Growth Rate %--Quick Ratio2.1Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %-8.0Current Ratio2.3Lower Leverage y-yN
Price/Free Cash Flow18.0y-y EBITDA Growth Rate %21.4ROA % (ttm)8.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)13.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M69.2ROIC % (ttm)13.9Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

MYGN is held by these investors:

MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ford AlexanderPresident, MGL 2017-11-13Sell3,031$31.643.89view
HENDERSON JOHN TDirector 2017-09-01Sell30,000$30.38.48view
HENDERSON JOHN TDirector 2017-02-23Buy6,000$18.6676.15view
HENDERSON JOHN TDirector 2016-09-12Sell30,000$20.4960.42view
Capone Mark ChristopherPresident & C.E.O. 2016-08-19Buy10,000$21.2454.76view
McDade Ralph LPresident Myriad RBM, Inc. 2016-08-12Buy1,000$21.4952.95view
Ford AlexanderPresident, MGL 2016-06-21Sell18,637$30.876.48view
King Gary A.Exec. VP International Ops 2016-04-06Sell15,000$39.03-15.78view
King Gary A.Exec. VP International Ops 2016-04-01Sell15,000$38.12-13.77view
GILBERT WALTER PHDDirector 2015-12-11Sell5,000$42.23-22.16view

Press Releases about MYGN :

Quarterly/Annual Reports about MYGN:

News about MYGN:

Articles On GuruFocus.com
Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Te Nov 10 2017 
Myriad Genetics to Present at the 2017 Jefferies London Healthcare Conference Nov 09 2017 
Myriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Developm Nov 06 2017 
Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Ma Nov 02 2017 
Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Ann Oct 30 2017 
EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women w Oct 26 2017 
Myriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017 Oct 24 2017 
Myriad Submits BRACAnalysis® CDx Application for Regulatory Approval in Japan for HER2- Metastati Oct 24 2017 
GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Re Oct 19 2017 
Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagn Oct 18 2017 

More From Our Partners
Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain Nov 23 2017 - ZACKS
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat